R. M. Steinman, D. Hawiger, and M. C. Nussenzweig, Tolerogenic dendritic cells, Annu. Rev. Immunol, vol.21, pp.685-711, 2003.

D. Raïch-regué, M. Glancy, and A. W. Thomson, Regulatory dendritic cell therapy: from rodents to clinical application, Immunol. Lett, vol.161, pp.216-221, 2014.

K. Sato, N. Yamashita, and T. Matsuyama, Human peripheral blood monocyte-derived interleukin-10-induced semi-mature dendritic cells induce anergic CD4(+) and CD8(+) T cells via presentation of the internalized soluble antigen and cross-presentation of the phagocytosed necrotic cellular fragments, Cell. Immunol, vol.215, pp.186-194, 2002.

V. Mirenda, I. Berton, J. Read, T. Cook, J. Smith et al., Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation, J. Am. Soc. Nephrol, vol.15, pp.987-997, 2004.

T. Taner, H. Hackstein, Z. Wang, A. E. Morelli, and A. W. Thomson, Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival, Am. J. Transplant, vol.5, pp.228-236, 2005.

H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang et al., Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance, J. Immunol, vol.178, pp.7018-7031, 2007.

J. Li, A. Meinhardt, M. E. Roehrich, D. Golshayan, J. Dudler et al., Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival, Am. J. Physiol. Heart Circ. Physiol, vol.293, pp.3415-3423, 2007.

L. Lu, W. C. Lee, T. Takayama, S. Qian, A. Gambotto et al., Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig), J. Leukoc. Biol, vol.66, pp.293-296, 1999.

H. Pêche, B. Trinité, B. Martinet, and M. C. Cuturi, Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors, Am. J. Transplant, vol.5, pp.255-267, 2005.

M. B. Lutz, R. M. Suri, M. Niimi, A. L. Ogilvie, N. A. Kukutsch et al., Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo, Eur. J. Immunol, vol.30, pp.1813-1822, 2000.

H. A. Depaz, O. O. Oluwole, A. O. Adeyeri, P. Witkowski, M. X. Jin et al., Immature rat myeloid dendritic cells generated in low-dose granulocyte macrophage-colony stimulating factor prolong donor-specific rat cardiac allograft survival, Transplantation, vol.75, pp.521-528, 2003.

Q. Wang, M. Zhang, G. Ding, Y. Liu, Y. Sun et al., Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo, Immunol. Lett, vol.90, pp.33-42, 2003.

M. Garrovillo, A. Ali, H. A. Depaz, R. Gopinathan, O. O. Oluwole et al., Induction of transplant tolerance with immunodominant allopeptide-pulsed host lymphoid and myeloid dendritic cells, Am. J. Transplant, vol.1, pp.129-137, 2001.

M. Garrovillo, A. Ali, and S. F. Oluwole, Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells, Transplantation, vol.68, pp.1827-1834, 1999.

S. Yamazaki, T. Iyoda, K. Tarbell, K. Olson, K. Velinzon et al., Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells, J. Exp. Med, vol.198, pp.235-247, 2003.

J. C. Ochando, C. Homma, Y. Yang, A. Hidalgo, A. Garin et al., Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts, Nat. Immunol, vol.7, pp.652-662, 2006.

S. F. Yates, A. M. Paterson, K. F. Nolan, S. P. Cobbold, N. J. Saunders et al., Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation, J. Immunol, vol.179, pp.967-976, 2007.

S. Fujita, Y. Sato, K. Sato, K. Eizumi, T. Fukaya et al., Regulatory dendritic cells protect against cutaneous chronic graftversus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells, Blood, vol.110, pp.3793-3803, 2007.

G. Bériou, H. Pêche, C. Guillonneau, E. Merieau, and M. C. Cuturi, Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression, Transplantation, vol.79, pp.969-972, 2005.

W. P. Min, D. Zhou, T. E. Ichim, X. Xia, X. Zhang et al., Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells, Transplantation, vol.75, pp.1160-1165, 2003.

D. Zhou, C. O'brien, J. Shum, B. Garcia, W. Min et al., LF 15-0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model, Transplantation, vol.76, pp.644-650, 2003.

J. Yang, S. M. Bernier, T. E. Ichim, M. Li, X. Xia et al., LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity, J. Leukoc. Biol, vol.74, pp.438-447, 2003.

M. Segovia, C. Louvet, P. Charnet, A. Savina, G. Tilly et al., Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation, Am. J. Transplant, vol.14, pp.1021-1031, 2014.

A. B. Cosimi, R. B. Colvin, R. C. Burton, R. H. Rubin, G. Goldstein et al., Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts, N. Engl. J. Med, vol.305, pp.308-314, 1981.

P. Vigeral, N. Chkoff, L. Chatenoud, H. Campos, M. Lacombe et al., Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent, Transplantation, vol.41, pp.730-733, 1986.

L. Chatenoud and J. A. Bluestone, CD3-specific antibodies: a portal to the treatment of autoimmunity, Nat. Rev. Immunol, vol.7, pp.622-632, 2007.

S. You, J. Zuber, C. Kuhn, M. Baas, F. Valette et al., Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing, Am. J. Transplant, vol.12, pp.2909-2919, 2012.

R. Goto, S. You, M. Zaitsu, L. Chatenoud, and K. J. Wood, Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells, Am. J. Transplant, vol.13, pp.1655-1664, 2013.

M. Segovia, M. C. Cuturi, and M. Hill, Preparation of mouse bone marrow-derived dendritic cells with immunoregulatory properties, Methods Mol. Biol, vol.677, pp.161-168, 2011.

J. A. Smith, J. Y. Tso, M. R. Clark, M. S. Cole, and J. A. Bluestone, Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy, J. Exp. Med, vol.185, pp.1413-1422, 1997.

L. Graca, S. P. Cobbold, and H. Waldmann, Identification of regulatory T cells in tolerated allografts, J. Exp. Med, vol.195, pp.1641-1646, 2002.

S. P. Cobbold, E. Adams, L. Graca, S. Daley, S. Yates et al., Immune privilege induced by regulatory T cells in transplantation tolerance, Immunol. Rev, vol.213, pp.239-255, 2006.

M. C. Baas, A. Besançon, B. Sawitzki, C. Mangez, F. Valette et al., Intragraft mechanisms associated with the immunosuppressive versus the tolerogenic effect of CD3 antibodies in a mouse model of islet allografts, Transplant. Proc, vol.45, pp.1895-1898, 2013.

C. Penaranda, Q. Tang, and J. A. Bluestone, Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory t cells, J. Immunol, vol.187, pp.2015-2022, 2011.

M. M. Tiao, L. Lu, R. Tao, L. Wang, J. J. Fung et al., Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity, Ann. Surg, vol.241, pp.497-505, 2005.

M. Hill, P. Thebault, M. Segovia, C. Louvet, G. Bériou et al., Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and epstein-barr virus-induced gene 3, Am. J. Transplant, vol.11, pp.2036-2045, 2011.

O. P. Joffre, E. Segura, A. Savina, and S. Amigorena, Cross-presentation by dendritic cells, Nat. Rev. Immunol, vol.12, pp.557-569, 2012.

G. Darrasse-jèze, S. Deroubaix, H. Mouquet, G. D. Victora, T. Eisenreich et al., Feedback control of regulatory T cell homeostasis by dendritic cells in vivo, J. Exp. Med, vol.206, pp.1853-1862, 2009.

C. I. Kingsley, M. Karim, A. R. Bushell, and K. J. Wood, CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4-and IL-10-dependent immunoregulation of alloresponses, J. Immunol, vol.168, pp.1080-1086, 2002.

K. J. Wood and S. Sakaguchi, Regulatory T cells in transplantation tolerance, Nat. Rev. Immunol, vol.3, pp.199-210, 2003.

A. R. Kendal, Y. Chen, F. S. Regateiro, J. Ma, E. Adams et al., Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance, J. Exp. Med, vol.208, pp.2043-2053, 2011.

M. Naranjo-gómez, D. Raïch-regué, C. Oñate, L. Grau-lópez, C. Ramo-tello et al., Comparative study of clinical grade human tolerogenic dendritic cells, J. Transl. Med, vol.9, p.89, 2011.

M. A. Boks, J. R. Kager-groenland, M. S. Haasjes, J. J. Zwaginga, S. M. Van-ham et al., IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction-a comparative study of human clinical-applicable DC, Clin. Immunol, vol.142, pp.332-342, 2012.

K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-ruiz, L. Taylor et al., Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N. Engl. J. Med, vol.346, pp.1692-1698, 2002.

B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman et al., Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes, N. Engl. J. Med, vol.352, pp.2598-2608, 2005.

B. Keymeulen, M. Walter, C. Mathieu, L. Kaufman, F. Gorus et al., Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass, Diabetologia, vol.53, pp.614-623, 2010.

N. Sherry, W. Hagopian, J. Ludvigsson, S. M. Jain, J. Wahlen et al., Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial, Protégé Trial Investigators, vol.378, pp.487-497, 2011.